Product Description
Ethambutol is a medication used in the management and treatment of tuberculosis. It is a bacteriostatic drug that inhibits cell wall synthesis. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK559050/)
Mechanisms of Action: Arabinosyl Transferase Inhibitor,Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Insmed
Company Location: BRIDGEWATER NJ 08807
Company CEO: William H. Lewis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Denmark, Germany, Israel, Italy, Japan, Korea, New Zealand, Spain, Taiwan, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Communicable Diseases|Mycobacterium Infections|Mycobacterium Infections, Nontuberculous|Mycobacterium avium-intracellulare Infection|Nontuberculous Mycobacterial Lung Disease
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MAC-LD | P3 |
Active, not recruiting |
Mycobacterium avium-intracellulare Infection|Mycobacterium Infections |
2025-07-17 |
|
| SPR720-102 | P1 |
Completed |
Healthy Volunteers |
2024-01-30 |
28% |
| SPR720-102 | P1 |
Completed |
Healthy Volunteers |
2024-01-30 |
28% |
| ARISE | P3 |
Completed |
Mycobacterium avium-intracellulare Infection|Mycobacterium Infections, Nontuberculous|Communicable Diseases |
2023-05-09 |
|
| ARISE | P3 |
Active, not recruiting |
Nontuberculous Mycobacterial Lung Disease |
2022-08-22 |